Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
| ▸ | GANAB | Q14697 | 1/20 | 0.62 |
| ▸ | GLB1 | P16278 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | AGL | P35573 | 2/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | MAN2B1 | O00754 | 1/20 | 0.43 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19328384 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL2434766 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL9495785 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL612200 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL14246910 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL7032907 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| SCHEMBL23531404 | 1.00 | GBA1 (0.62) | GBA1GANABGLB1MGAMGAA | |
| Hydrochloric Acid SCHEMBL9496174 | 0.98 | GBA1 (0.60) | GBA1GANABGLB1MGAMGAA | |
| Hydrochloric Acid SCHEMBL9497390 | 0.98 | GBA1 (0.60) | GBA1GANABGLB1MGAMGAA | |
| Hydrochloric Acid SCHEMBL960466 | 0.98 | GBA1 (0.60) | GBA1GANABGLB1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | GBA1 18/4885GANAB 175/4885GLB1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.